Medical Cannabis Program
A state-level regulatory framework allowing patients with qualifying conditions to legally access cannabis for medical purposes under physician supervision.
In Depth
As of 2024, 38 US states have medical cannabis programs. Qualifying conditions vary by state but commonly include cancer, epilepsy, chronic pain, PTSD, MS, and HIV/AIDS. Most programs require physician certification, patient registration, and purchase from licensed dispensaries. Medical cannabis programs operate in conflict with federal law (Schedule I), creating legal uncertainty for patients, physicians, and businesses. The quality and standardization of medical cannabis products varies substantially between states.
Related Terms
More in Regulatory
Schedule I
The most restrictive classification under the US Controlled Substances Act (CSA), applied to substances deemed to have high abuse potential, no accepted medical use, and lack of accepted safety under medical supervision.
IND (Investigational New Drug)
An application submitted to the FDA allowing a pharmaceutical company or researcher to begin clinical trials of an unapproved drug in humans.
NCT Number
A unique identifier assigned by ClinicalTrials.gov to every registered clinical study. Format: NCT followed by 8 digits (e.g., NCT04849910).
GMP (Good Manufacturing Practice)
A system of regulations ensuring that products are consistently produced and controlled according to quality standards. Required for pharmaceutical-grade cannabinoid products.
DEA (Drug Enforcement Administration)
The US federal agency responsible for enforcing controlled substances laws. Administers the scheduling system under the Controlled Substances Act.